Celularity Inc
For the period ended Sep 30, 2023. Filed Jan 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2023 · Filed Jan 3, 2024
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Stoc kholders’ Equity (Unaudited)
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||
| Balances at December 31, 2022 | 148,921,287 | $15 | $844,373 | $(645,496) | $9 | $198,901 | |
| Exercise of stock options | 1,071,000 | - | 300 | - | - | 300 | |
| Common stock issued pursuant to short-term debt conversion | 3,656,118 | 1 | 3,509 | - | (152) | 3,358 | |
| Issuance of common stock in PIPE Offering, net of offering expenses | 9,381,841 | 1 | 8,930 | - | - | 8,931 | |
| Issuance of common stock for stem-cells to be used in research and development | 1,694,915 | - | 1,000 | - | - | 1,000 | |
| Vesting of restricted stock units | 253,390 | - | - | - | - | - | |
| Tax withholding on vesting of restricted stock units | (81,095) | - | (53) | - | - | (53) | |
| Issuance of common stock under ATM Agreement | 132,958 | - | 136 | - | - | 136 | |
| Issuance of warrants on senior secured bridge loan | - | - | 274 | - | - | 274 | |
| Stock-based compensation expense | - | - | 3,988 | - | - | 3,988 | |
| Change in fair value of debt due to change in credit risk, net of tax | - | - | - | - | 2,810 | 2,810 | |
| Net loss | - | - | - | (64,017) | - | (64,017) | |
| Balances at March 31, 2023 | 165,030,414 | $17 | $862,457 | $(709,513) | $2,667 | $155,628 | |
| Exercise of stock options | 15,371 | - | 4 | - | - | 4 | |
| Common stock issued pursuant to short-term debt conversion | 380,848 | - | 282 | - | (10) | 272 | |
| Issuance of common stock in PIPE Offering, net of offering expenses | 5,813,945 | - | 3,750 | - | - | 3,750 | |
| Issuance of common stock in Registered Direct Offering, net of offering expenses | 9,230,770 | 1 | 1,225 | - | - | 1,226 | |
| Vesting of restricted stock units | 391,782 | - | - | - | - | - | |
| Tax withholding on vesting of restricted stock units | (45,885) | - | (33) | - | - | (33) | |
| Issuance of warrants on senior secured bridge loans | - | - | 2,016 | - | - | 2,016 | |
| Stock-based compensation expense | - | - | 3,856 | - | - | 3,856 | |
| Change in fair value of debt due to change in credit risk, net of tax | - | - | - | - | (269) | (269) | |
| Net loss | - | - | - | (47,949) | - | (47,949) | |
| Balances at June 30, 2023 | 180,817,245 | $18 | $873,557 | $(757,462) | $2,388 | $118,501 | |
| Common stock issued pursuant to short-term debt conversion | 1,557,848 | - | 807 | - | 7 | 814 | |
| Issuance of common stock in Registered Direct Offering, net of offering expenses | 8,571,429 | 1 | 95 | - | - | 96 | |
| Common stock issued pursuant to short-term debt maturity extension | 2,707,308 | - | 712 | - | - | 712 | |
| Fair value of warrant modification for professional services | - | - | 403 | - | - | 403 | |
| Vesting of restricted stock units | 8,052 | - | - | - | - | - | |
| Tax withholding on vesting of restricted stock units | (2,749) | - | (1) | - | - | (1) | |
| Stock-based compensation expense | - | - | 3,598 | - | - | 3,598 | |
| Net loss | - | - | - | (93,876) | - | (93,876) | |
| Balances at September 30, 2023 | 193,659,133 | $19 | $879,171 | $(851,338) | $2,395 | $30,247 | |
| Balances at December 31, 2021 | 124,307,884 | $12 | $763,087 | $(663,681) | $ | - | $99,418 |
| Cumulative effect adjustment ASU 2016-02 | - | - | - | 3,996 | - | 3,996 | |
| Reclassification of previously exercised stock options | 131,253 | - | 441 | - | - | 441 | |
| Exercise of warrants | 13,281,386 | 2 | 46,483 | - | - | 46,485 | |
| Exercise of stock options | 10,255 | - | 21 | - | - | 21 | |
| Purchase and retirement of common shares | (3,058) | - | (11) | - | - | (11) | |
| Stock-based compensation expense | - | - | 2,422 | - | - | 2,422 | |
| Net loss | - | - | - | (62,867) | - | (62,867) | |
| Balances at March 31, 2022 | 137,727,720 | $14 | $812,443 | $(722,552) | $ | - | $89,905 |
| Cumulative effect adjustment ASU 2016-02 | - | - | - | (3) | - | (3) | |
| Issuance of common stock to PIPE investor, net of issuance costs | 4,054,055 | - | 7,651 | - | - | 7,651 | |
| Exercise of warrants | 304 | - | 4 | - | - | 4 | |
| Exercise of stock options | 609,529 | - | 313 | - | - | 313 | |
| Purchase and retirement of common shares | (7,441) | - | (75) | - | - | (75) | |
| Stock-based compensation expense | - | - | 4,529 | - | - | 4,529 | |
| Net income | - | - | - | 47,826 | - | 47,826 | |
| Balances at June 30, 2022 | 142,384,167 | $14 | $824,865 | $(674,729) | $ | - | $150,150 |
| Exercise of warrants | 100 | - | 1 | - | - | 1 | |
| Exercise of stock options | 322,093 | - | 399 | - | - | 399 | |
| Issuance of common stock in ATM offering, net of commissions and offering expenses | 1,817,830 | - | 4,131 | - | - | 4,131 | |
| Stock-based compensation expense | - | - | 4,519 | - | - | 4,519 | |
| Change in fair value of debt due to change in credit risk, net of tax | - | - | - | - | 236 | 236 | |
| Net income | - | - | - | 4,799 | - | 4,799 | |
| Balances at September 30, 2022 | 144,524,190 | $14 | 833,915 | $(669,930) | $236 | $164,235 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.